15 Years of AMNOG: What Ticagrelor and Colchicine Reveal About the Evolution of Benefit Assessment

In 2011, ticagrelor had to demonstrate added benefit against the antithrombotic comparators of the time. In 2026, colchicine was assessed as an add-on to comprehensive standard treatment. More than half of the patients in the pivotal COLCOT trial were already receiving ticagrelor as concomitant medication.

The comparison also reveals continuity: despite extensive clinical dossier documentation, usable health-related quality-of-life data were still missing from the assessments examined.

Ticagrelor in 2011, 2016 and 2026: From the First AMNOG Assessment to Standard Treatment

Ticagrelor's changing role can be traced across three milestones: the first AMNOG procedure in 2011, reassessment in secondary prevention in 2016, and its use as background treatment in the colchicine assessment in 2026.

On 15 December 2011, Germany's Federal Joint Committee (G-BA) adopted its decision on the added benefit of ticagrelor (Brilique). The indication covered prevention of atherothrombotic events in adults with acute coronary syndrome.

The 2011 procedure marked the start of early benefit assessment under Section 35a of the German Social Code Book V (§ 35a SGB V). How the AMNOG process in Germany is structured, and what role the appropriate comparator therapy plays in it, is explained in the corresponding guide.

The first assessment already differentiated between patient groups and treatment strategies. For unstable angina or non-ST-elevation myocardial infarction (UA/NSTEMI), the G-BA found proof of considerable added benefit. In the three STEMI settings, added benefit was generally not proven, although exceptions applied to certain subpopulations within the STEMI/PCI group.

A further assessment followed on 15 September 2016, covering adults with a history of myocardial infarction and a high risk of further atherothrombotic events. Acetylsalicylic acid (ASA) monotherapy was the zweckmäßige Vergleichstherapie (zVT), the comparator specified under Germany's AMNOG framework. The G-BA found an indication (Anhaltspunkt) of minor added benefit.

Ticagrelor had therefore been assessed in a setting directly relevant to the later colchicine procedure: prevention of further cardiovascular events following myocardial infarction.

In the 2026 colchicine assessment, the G-BA specified optimised standard therapy as the zVT. According to the guidelines considered by the G-BA, this includes dual antiplatelet therapy (DAPT) with ASA plus ticagrelor, prasugrel or clopidogrel. Ticagrelor was one possible component of background treatment, not the sole formally specified comparator.

The trial data make this connection tangible. At randomisation, 52.4% of patients in the colchicine arm and 53.0% in the placebo arm were receiving ticagrelor. The drug first assessed under AMNOG was thus already used by around half the participants in the pivotal trial supporting a subsequent assessment.

Colchicine in 2026: Optimised Standard Therapy Changes the Assessment Question

In the colchicine procedure, IQWiG had to determine whether the background treatment used in COLCOT adequately reflected the optimised standard therapy specified by the G-BA.

This encompassed secondary prevention following myocardial infarction and treatment of comorbidities such as hypertension, heart failure and diabetes mellitus.

The randomised, placebo-controlled COLCOT trial ran from December 2015 to July 2019. Its final data cut-off was 28 August 2019, while the AMNOG dossier was submitted on 27 February 2026. Approximately six and a half years separated the final data cut-off from the benefit assessment.

IQWiG examined antithrombotic treatment, lipid-lowering therapy and other cardiovascular concomitant treatments. Detailed information on DAPT duration and possible de-escalation strategies was missing. The assessment of lipid-lowering treatment was limited by the absence of LDL cholesterol measurements and statin dose information. For a large proportion of participants with type 2 diabetes, guideline-concordant treatment with an SGLT2 inhibitor or GLP-1 receptor agonist was not ensured.

IQWiG nevertheless did not exclude COLCOT. Overall, concomitant treatment largely reflected guideline recommendations, and the institute did not assume that a relevant proportion of the trial population had received inadequate care. COLCOT was included in the benefit assessment, although the uncertainties reduced the certainty of the conclusions.

A clinical trial therefore needs to do more than demonstrate an effect against its control group. Its findings must also be interpretable against the care standards relevant at the time of assessment. That requires sufficiently detailed documentation of the background treatment actually administered.

AMNOG Dossiers in 2011 and 2026: More Documentation, Persistent Evidence Gaps

The clinical dossier documents examined have grown in volume, but the first AMNOG assessment already involved substantial methodological work.

How an AMNOG dossier is structured and what each module requires is described in the dossier guide.

Module 4 of the 2011 ticagrelor dossier contained 296 numbered pages. It already included a systematic literature search, risk-of-bias assessments, subgroup and sensitivity analyses, and an adjusted indirect comparison between ticagrelor and prasugrel. Module 4 A for the 2016 ticagrelor reassessment comprised 416 numbered pages.

For colchicine in 2026, Module 4 A comprised 376 numbered pages. A separate 564-page Appendix 4-G provided further results, including sensitivity and subgroup analyses.

These figures refer to the numbered pages of the specified documents. They are not a standardised comparison of the total body of evidence across procedures.

Health-Related Quality of Life: An Evidence Gap Spanning 15 Years

The G-BA's 2011 ticagrelor decision noted that no usable health-related quality-of-life data were available. This outcome was not collected in the 2016 reassessment either. Although EQ-5D visual analogue scale data on general health status were available, they were considered under morbidity.

COLCOT likewise did not collect outcomes in the health-related quality-of-life category. Suitable evidence for this dimension was therefore absent in all three assessments examined.

For colchicine, limitations also affected the safety assessment. IQWiG found no suitable data for serious adverse events or discontinuation due to adverse events. Serious bleeding could not be assessed using suitable data either. Together with uncertainties about background treatment, these gaps limited the certainty of the conclusions, even though the trial's overall risk of bias was assessed as low.

Further methodological analyses can examine the available evidence more closely and improve transparency. They cannot replace patient-relevant outcomes that were never collected in the clinical programme.

15 Years of AMNOG: Standards of Care Evolve, and Evidence Must Remain Relevant

The ticagrelor and colchicine cases illustrate how medicines help shape future standards of care and how clinical evidence is assessed against those standards years after it was generated.

In 2011, ticagrelor was evaluated as a new treatment against existing antithrombotic options. In 2016, it was assessed for secondary prevention. By the 2026 colchicine procedure, it formed part of the background treatment for a substantial proportion of the COLCOT population.

At the same time, COLCOT had to address an assessment question framed within the care context of 2026. The trial remained suitable, but uncertainties about concomitant treatment and missing outcome data limited the certainty of its findings.

The fundamental AMNOG question remains: what patient-relevant added benefit does a medicine offer compared with the G-BA's specified comparator? The therapeutic context in which that question is answered continues to change. And even a very extensive dossier can only analyse evidence that was actually collected.

Sources

1. , 15 December 2011. https://www.g-ba.de/downloads/39-261-1418/2011-12-15G-BA: Decision on ticagrelorAM-RL-XIITicagrelor_BAnz.pdf
2. AstraZeneca: Ticagrelor, Module 4 A, 30 June 2011 (original dossier).
3. nal indication, 15 September 2016. https://www.g-ba.de/downloads/39-261-2703/2016-09-15G-BA: Decision on ticagrelor, additioAM-RL-XIITicagrelornAWGD-220_BAnz.pdf
4. AstraZeneca: Ticagrelor, Module 4 A, 2016 (original dossier).
5. APONTIS PHARMA: Colchicine (Colxi), Module 4 A, 27 February 2026 (original dossier).
6. APONTIS PHARMA: Colchicine, Module 4 A, Appendix 4-G, 27 February 2026.
7. IQWiG: Colchicine, dossier assessment A26-16, 28 May 2026, especially Table 8 and Sections I 3–I 5. https://doi.org/10.60584/A26-16